Samrat Pharmachem Ltd (SAMRATPH) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Samrat Pharmachem Ltd on NSE and BSE, with an AI summary of each filing.
Samrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Samrat Pharmachem Limited ....
Intimation · 14 Nov 2026, 5:30 am
Samrat Pharmachem Schedules Board Meeting for Q2 Results Samrat Pharmachem Limited has notified BSE that its Board of Directors will meet on 14th Nov'26 at 02:00 PM at its Mumbai corporate office. The board will primarily consider, approve, and take on record the company's un-audited financial results under Ind-AS for the quarter ended 30th Sep'26. The results will be intimated to the exchange, published in the press, and uploaded to the company's official website post-meeting.
The share holders of the company at the 34th AGM held on 23-09-2026, have approved the appointment of M/s. Divyesh J Shah & Associates, Chartered Accountants as Statutory Auditors of the ....
Change in Auditor · 24 Sept 2026, 9:45 pm
Scrutinizer''s Report & Voting Results for 34th AGM
Annual General Meeting · 24 Sept 2026, 8:46 pm
The Company''s 34th AGM was held on 23rd September 2026 and the business mentioned in the prior notice was transacted.
Annual General Meeting · 23 Sept 2026, 10:07 pm
34th Annual General Meeting of the company will be held on Wednesday, September 23, 2026 at 1:00 PM (IST) through Video Conferencing (VC) / Other Audio Video Means (OAVM)
Annual General Meeting · 28 Aug 2026, 2:07 am
34th Annual Report for the Financial Year 2025-26
Others (Uncategorized) · 28 Aug 2026, 1:34 am
The Board considered and adopted the unaudited financial results for the quarter ended June 30, 2026
Outcome · 15 Aug 2026, 1:44 am
Samrat Pharmachem Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 7,976 (+5.4% YoY | +11.1% QoQ) ■ EBITDA: 89.9 (+622.6% YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 1.1 (+96 bps YoY | Loss to Profit QoQ) ■ PAT: 87.6 (Loss to Profit YoY | Loss to Profit QoQ) ■ EPS (INR): 2.84 (Loss to Profit YoY | Loss to Profit QoQ)
Appointment of Statutory Auditors for the company from 34th Annual General Meeting to 39th Annual General Meeting
Change in Auditor · 17 Jul 2026, 9:14 pm
Samrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Approval of Un-Audited Financial ....
Intimation · 14 Aug 2026, 5:30 am
Samrat Pharmachem Sets Board Meeting for Q1 FY27 Results Samrat Pharmachem (BSE: 530125) will hold a Board of Directors meeting on 14th Aug'26 to consider and approve its un-audited financial results for the first quarter ending 30th Jun'26. The meeting is scheduled for 02:00 PM at the company's corporate office in Mumbai. The results will be disclosed to the stock exchanges post-meeting, as per SEBI regulations. This announcement is a key upcoming catalyst for the company's stock, with investors awaiting Q1 performance data.
The Board considered and adopted the financial results for the quarter and year ended March 31, 2026
Outcome · 31 May 2026, 2:18 am
Samrat Pharmachem Reports Q4'26 & FY26 Results, Swings to Annual Loss Samrat Pharmachem reported a net loss of ₹203.63 lakhs for Q4'26, compared to a loss of ₹39.92 lakhs in Q4'25. For the full year FY26, the company posted a net loss of ₹331.20 lakhs, a significant decline from a net profit of ₹711.22 lakhs in FY25. FY26 revenue from operations was flat at ₹28,972.12 lakhs versus ₹28,586.05 lakhs YoY. The board also announced the 34th AGM will be held on 23-Sep'26, with the register of members closed from 17-Sep'26 to 23-Sep'26.
Audited Financial Results for the quarter and year ended 31st March, 2026
Financial Result · 31 May 2026, 2:15 am
Samrat Pharmachem Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) ■ Revenue: 7,177 (+0.8% YoY | +13.2% QoQ) ■ EBITDA: -124 (Profit to Loss YoY | -89.5% QoQ) ■ EBITDA Margin (%): -1.7 (Profit to Loss YoY | -70 bps QoQ) ■ PAT: -204 (-410.1% YoY | -343.2% QoQ) ■ EPS (INR): -6.59 (-410.9% YoY | -342.3% QoQ)
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 07 Apr 2026, 8:31 pm
Samrat Pharmachem Confirms It Is Not a Large Corporate On 07-Apr'26, Samrat Pharmachem Limited (BSE: 530125) formally declared to the exchange that it does not meet the criteria to be classified as a "Large Corporate" under the SEBI circular dated Nov 26, 2018. This regulatory filing confirms its non-applicability for the mandatory borrowing framework. The company also reported zero outstanding borrowings as of the most recent reporting period and holds no credit rating. This status exempts it from the requirement to raise a portion of its incremental borrowings via debt securities.
Crisil Limited has upgraded its rating to CRISIL BB/STABLE/ CRISILA4+
Others (Uncategorized) · 30 Mar 2026, 8:09 pm
Samrat Pharmachem's Credit Rating Upgraded by Crisil Crisil has upgraded Samrat Pharmachem's (BSE: 530125) credit rating on its bank facilities to 'Crisil BB/Stable/Crisil A4+' from 'Crisil BB+/Negative/Crisil A4+'. The rating action, announced on 30 Mar, '26, signals an improved credit profile and a shift from a negative to a stable outlook, which is a positive catalyst for the company's financial flexibility and cost of borrowing.
Samrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited Financial Results ....
Intimation · 30 May 2026, 5:30 am
Samrat Pharmachem Sets Board Meeting for FY26 Financial Results Samrat Pharmachem Limited's Board of Directors will meet on 30th May'26 to consider and approve the Audited Standalone Financial Results for the financial year ending 31st Mar'26. The meeting will also review the Statutory Auditor's Report for the same period. This announcement was made to the BSE on 25th Mar'26, in compliance with SEBI LODR regulations.
The Board has considered and took on record the Un-audited financial results of the company for the quarter ended December 31, 2025.
Outcome · 13 Feb 2026, 11:39 pm
Samrat Pharmachem Reports Net Loss in Q3 FY26 on Revenue Decline Samrat Pharmachem reported a net loss of ₹45.95 lakhs for Q3 FY26, a significant downturn from a profit of ₹278.48 lakhs in Q3 FY25. Revenue from operations declined marginally by 0.4% YoY to ₹6,342.61 lakhs. On a sequential basis, revenue fell 19.6% QoQ, while the net loss narrowed from ₹58.73 lakhs in Q2 FY26. Total expenses increased 7.8% YoY to ₹6,439.42 lakhs. The company's EPS for the quarter was negative at (₹1.49). For the nine months ended 31st Dec'25, the company posted a net loss of ₹127.57 lakhs.
The Board has considered and took on record the un-audited standalone financial results for the quarter ended December 31, 2025.
Financial Result · 13 Feb 2026, 11:35 pm
Samrat Pharmachem Limited - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakhs) ■ Revenue: 6343 (-0.4% YoY | -19.6% QoQ) ■ EBITDA: -65.7 (Profit to Loss YoY | -81.1% QoQ) ■ EBITDA Margin (%): -1.0 (Profit to Loss YoY | -58 bps QoQ) ■ PAT: -46.0 (Profit to Loss YoY | +21.8% QoQ) ■ EPS (INR): -1.49 (Profit to Loss YoY | +21.6% QoQ)
Samrat Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve the un-audited financial ....
Intimation · 13 Feb 2026, 5:30 am
Samrat Pharmachem Board to Approve Q3FY26 Results on Feb 13 Samrat Pharmachem (BSE: 530125) has scheduled a Board of Directors meeting on 13th Feb'26. The agenda includes the consideration and approval of the company's un-audited financial results for the quarter ended 31st Dec'25. This meeting is crucial for assessing the company's performance in the third quarter of the fiscal year 2026.
Crisil Ltd has downgraded its rating to "CrisilBB+/Negative/CrisilA4+"
Others (Uncategorized) · 02 Dec 2025, 8:57 pm
Samrat Pharmachem's Credit Rating Downgraded by Crisil On 2nd Dec'25, Crisil Limited downgraded Samrat Pharmachem's rating on its Rs. 30 crore bank facilities to 'Crisil BB+/Negative/Crisil A4+' from 'Crisil BBB-/Stable/Crisil A3'. The downgrade reflects a deterioration in the company's business risk profile, primarily driven by a decline in its operating margin to negative 0.14% in H1 FY26. This action affects a Rs. 28 crore cash credit facility, now rated 'Crisil BB+/Negative', and a Rs. 2 crore foreign exchange forward facility, rated 'Crisil A4+'. Despite the downgrade, the company maintains a healthy financial risk profile with a networth of Rs. 71.8 crore as of 31st Mar'25, but faces weaknesses from raw material price volatility and a modest working capital cycle.
Un-audited financial results for the quarter and half year ended 30th September, 2025
Financial Result · 15 Nov 2025, 2:14 am
The Board of Directors considered and took on record the Un-audited Standalone Financial Results for the quarter and half year ended September 30, 2025.
Outcome · 15 Nov 2025, 2:05 am
The shareholders approved the dividend on equity shares for the FY: 2024-25 @ Re. 1/- per share of Rs. 10 each (10%)
Dividend · 27 Sept 2025, 7:10 pm
Scrutinizer Report & Voting Results for 33 AGM
Annual General Meeting · 27 Sept 2025, 6:47 pm
Samrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve the Un-audited financial ....
Intimation · 14 Nov 2025, 5:30 am
The Company''s 33rd AGM was held today and the business mentioned in the Notice dated July 16, 2025 was transacted.
Annual General Meeting · 25 Sept 2025, 9:09 pm
33rd Annual Report FY: 2024-25
Others (Uncategorized) · 04 Sept 2025, 7:27 pm